Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) EBITDA: 2023-2025

Historic EBITDA for Inhibrx Biosciences (INBX) over the last 3 years, with Sep 2025 value amounting to -$33.8 million.

  • Inhibrx Biosciences' EBITDA rose 27.75% to -$33.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.0 million, marking a year-over-year increase of 58.35%. This contributed to the annual value of -$331.4 million for FY2024, which is 51.19% down from last year.
  • Inhibrx Biosciences' EBITDA amounted to -$33.8 million in Q3 2025, which was down 23.45% from -$27.4 million recorded in Q2 2025.
  • Inhibrx Biosciences' 5-year EBITDA high stood at -$27.4 million for Q2 2025, and its period low was -$160.9 million during Q2 2024.
  • Its 3-year average for EBITDA is -$61.3 million, with a median of -$46.3 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 267.63% in 2024, then soared by 82.98% in 2025.
  • Over the past 3 years, Inhibrx Biosciences' EBITDA (Quarterly) stood at -$88.3 million in 2023, then skyrocketed by 43.45% to -$49.9 million in 2024, then increased by 27.75% to -$33.8 million in 2025.
  • Its EBITDA stands at -$33.8 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$42.9 million for Q1 2025.